XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Financial Instruments Measured at Fair Value | 6 Months Ended
--- | ---
Jul. 01, 2017
Fair Value Disclosures [Abstract] |
Financial Instruments Measured At Fair Value [Text Block] | Financial Instruments Measured at Fair Value Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The company utilizes a fair value hierarchy, which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. The fair value hierarchy has three levels of inputs that may be used to measure fair value:
Level 1 | Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
Level 2 | Quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 | Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable.
The following table presents assets (liabilities) measured at fair value on a recurring basis at July 1, 2017:
|  | Balance Sheet Location |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Cash equivalents |  | Other assets |  | $ | 893 |  |  | $ | — |  |  | $ | — |  |  | $ | 893 |
Available-for-sale securities |  | Other assets |  | 43,481 |  |  | — |  |  | — |  |  | 43,481 |
Interest rate swaps |  | Other assets |  | — |  |  | 300 |  |  | — |  |  | 300 |
Foreign exchange contracts |  | Other current assets |  | — |  |  | 6,490 |  |  | — |  |  | 6,490 |
Foreign exchange contracts |  | Accrued expenses |  | — |  |  | (8,714 | ) |  | — |  |  | (8,714 | )
Contingent consideration |  | Accrued expenses / Other liabilities |  | — |  |  | — |  |  | (2,959 | ) |  | (2,959 | )
|  |  |  | $ | 44,374 |  |  | $ | (1,924 | ) |  | $ | (2,959 | ) |  | $ | 39,491 |
The following table presents assets (liabilities) measured at fair value on a recurring basis at December 31, 2016:
|  | Balance Sheet Location |  | Level 1 |  | Level 2 |  | Level 3 |  | Total
Cash equivalents |  | Other assets |  | $ | 2,660 |  |  | $ | — |  |  | $ | — |  |  | $ | 2,660 |
Available-for-sale securities |  | Other assets |  | 37,915 |  |  | — |  |  | — |  |  | 37,915 |
Interest rate swaps |  | Other assets |  | — |  |  | 152 |  |  | — |  |  | 152 |
Foreign exchange contracts |  | Other current assets |  | — |  |  | 4,685 |  |  | — |  |  | 4,685 |
Foreign exchange contracts |  | Accrued expenses |  | — |  |  | (3,444 | ) |  | — |  |  | (3,444 | )
Contingent consideration |  | Accrued expenses / Other liabilities |  | — |  |  | — |  |  | (4,027 | ) |  | (4,027 | )
|  |  |  | $ | 40,575 |  |  | $ | 1,393 |  |  | $ | (4,027 | ) |  | $ | 37,941 |
Assets and liabilities that are measured at fair value on a nonrecurring basis relate primarily to goodwill and identifiable intangible assets (see Note C and D). The company tests these assets for impairment if indicators of potential impairment exist. During the first six months of 2017 and 2016, there were no transfers of assets (liabilities) measured at fair value between the three levels of the fair value hierarchy. Available-For-Sale Securities The company has an 8.4% equity ownership interest in Marubun Corporation ("Marubun") and a portfolio of mutual funds with quoted market prices, all of which are accounted for as available-for-sale securities. The fair value of the company's available-for-sale securities is as follows:
|  | July 1, 2017 |  | December 31, 2016
|  | Marubun |  | Mutual Funds |  | Marubun |  | Mutual Funds
Cost basis |  | $ | 10,016 |  |  | $ | 18,320 |  |  | $ | 10,016 |  |  | $ | 18,097 |
Unrealized holding gain |  | 6,446 |  |  | 8,699 |  |  | 3,806 |  |  | 5,996 |
Fair value |  | $ | 16,462 |  |  | $ | 27,019 |  |  | $ | 13,822 |  |  | $ | 24,093 |
The unrealized holding gains or losses on these investments are included in "Accumulated other comprehensive loss" in the shareholders' equity section in the company's consolidated balance sheets. Derivative Instruments The company uses various financial instruments, including derivative instruments, for purposes other than trading. Certain derivative instruments are designated at inception as hedges and measured for effectiveness both at inception and on an ongoing basis. Derivative instruments not designated as hedges are marked-to-market each reporting period with any unrealized gains or losses recognized in earnings. Interest Rate Swaps The company occasionally enters into interest rate swap transactions that convert certain fixed-rate debt to variable-rate debt or variable-rate debt to fixed-rate debt in order to manage its targeted mix of fixed- and floating-rate debt. The company uses the hypothetical derivative method to assess the effectiveness of its interest rate swaps designated as fair value hedges on a quarterly basis. The effective portion of the change in the fair value of designated interest rate swaps is recorded as a change to the carrying value of the related hedged debt. The ineffective portion of the interest rate swaps, if any, is recorded in "Interest and other financing expense, net" in the company's consolidated statements of operations. As of July 1, 2017 and December 31, 2016, all outstanding interest rate swaps were designated as fair value hedges. The terms of our outstanding interest rate swap contracts at July 1, 2017 are as follows:
Maturity Date |  | Notional Amount |  | Interest rate due from counterparty |  | Interest rate due to counterparty
April 2020 |  | 50,000 |  | 6.000% |  | 6 mo. USD LIBOR + 3.896%
Foreign Exchange Contracts The company’s foreign currency exposure relates primarily to international transactions where the currency collected from customers can be different from the currency used to purchase the product. The company’s transactions in its foreign operations are denominated primarily in the following currencies: Euro, Chinese Renminbi, British Pound, Taiwan Dollar, and Australian Dollar. The company enters into foreign exchange forward, option, or swap contracts (collectively, the "foreign exchange contracts") to mitigate the impact of changes in foreign currency exchange rates. These contracts are executed to facilitate the hedging of foreign currency exposures resulting from inventory purchases and sales and generally have terms of no more than six months. Gains or losses on these contracts are deferred and recognized when the underlying future purchase or sale is recognized or when the corresponding asset or liability is revalued. The company does not enter into foreign exchange contracts for trading purposes. The risk of loss on a foreign exchange contract is the risk of nonperformance by the counterparties, which the company minimizes by limiting its counterparties to major financial institutions. The fair value of the foreign exchange contracts are estimated using market quotes. The notional amount of the foreign exchange contracts at July 1, 2017 and December 31, 2016 was $447,484 and $460,233, respectively. Gains and losses related to non-designated foreign currency exchange contracts are recorded in "Cost of sales" in the company's consolidated statements of operations. Gains and losses related to designated foreign currency exchange contracts, are recorded in "Cost of sales", "Selling, general, and administrative expenses", and "Interest and other financing expense, net" based upon the nature of the underlying hedged transaction, in the company's consolidated statements of operations and were not material for the second quarter and first six months of 2017 and 2016. The effects of derivative instruments on the company's consolidated statements of operations and other comprehensive income are as follows:
|  | Quarter Ended |  | Six Months Ended
|  | July 1, 2017 |  | July 2, 2016 |  | July 1, 2017 |  | July 2, 2016
Gain (Loss) Recognized in Income |  |  |  |  |  |  |  |
Foreign exchange contracts |  | $ | (2,223 | ) |  | $ | 4,191 |  |  | $ | (11,162 | ) |  | $ | 521 |
Interest rate swaps |  | (163 | ) |  | (150 | ) |  | (321 | ) |  | (299 | )
Total |  | $ | (2,386 | ) |  | $ | 4,041 |  |  | $ | (11,483 | ) |  | $ | 222 |
Gain (Loss) Recognized in Other Comprehensive Income before reclassifications |  |  |  |  |  |  |  |
Foreign exchange contracts |  | $ | (1,043 | ) |  | $ | 543 |  |  | $ | (867 | ) |  | $ | (534 | )
Interest rate swaps |  | $ | (1,053 | ) |  | $ | — |  |  | $ | (1,053 | ) |  | $ | — |
Other The carrying amount of cash and cash equivalents, accounts receivable, net, and accounts payable approximate their fair value due to the short maturities of these financial instruments.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration